SpacePharma provides pharmaceutical and biological experiments to run under microgravity conditions. This is fully autonomous, AI-powered experiments in space—remotely, affordably, and at scale. Our miniaturized lab-on-a-chip platforms operate on the ISS, CubeSats, and private space missions, unlocking microgravity’s potential for drug discovery, protein development, materials innovation, and life science research. As a pioneer in outer space bioconvergence—the fusion of biology, AI, and space tech—we accelerate breakthroughs that go far beyond Earth’s limits. Since 2017, we've delivered end-to-end research services:exploitations design, spaceflight logistics, real-time remote control, and advanced data analysis. With missions through SpaceX, Axiom, and ESA, we’re helping science escape gravity—and bringing revolutionary discoveries back to Earth.
Looking for a particular SpacePharma employee's phone or email?
The SpacePharma annual revenue was $2 million in 2026.
Yair Feuchtwanger is the CTO of SpacePharma.
15 people are employed at SpacePharma.
The NAICS codes for SpacePharma are [54, 541, 54171, 541713, 5417].
The SIC codes for SpacePharma are [873, 87].